Navigation Links
UZH research team discovers the origins of key immune cells
Date:7/5/2012

Chronic inflammatory conditions are extremely common diseases in humans and in the entire animal kingdom. Both in autoimmune diseases and pathogen-caused diseases, the inflamed areas are rapidly colonized by antibody producing B lymphocytes which organize themselves in highly structured areas called "lymphoid follicles". The scaffold of such follicles is provided by follicular dendritic cells (FDCs). FDCs have important roles in the development of immune responses, since they trap antigens for protracted periods of, thereby training B lymphocytes to recognize the invaders. However, FDCs can also play deleterious roles in disease, because they can provide sanctuaries for infectious pathogens such as the human immunodeficiency virus and prions.

But where do FDCs come from? Because they can arise so quickly, it has been discussed that FDCs might arise from circulating blood cells. Conversely, if FDCs are immobile cells, they would have to be ubiquitous in order to support formation of lymphoid follicles in any given place of the body.

In a paper which is being published in the journal Cell, Dr. Nike Krutler in the team of Professor Adriano Aguzzi at the University of Zurich went after the latter question. Using novel markers identified in the Aguzzi laboratory in the past several years, they have identified clues suggesting that FDC precursor cells exist in the wall of blood vessels. This would explain many of the properties of FDCs, including the broad range of organs in which lymphoid follicles can arise during inflammatory conditions because blood vessels are present in most organs of the body.

The specific morphology of the putative FDC precursor cells suggested that they be identical with mural cells, pluripotent cells which decorate vessel walls. One typical marker of mural cells is platelet derived growth factor receptor β (PDGFR-β). However, FDCs do not express PDGFR-β. Aguzzi and colleagues reasoned that this may be due to mural cells losing expression of PDGFR-β during their maturation into FDCs. In order to test this hypothesis, they used a sophisticated cell-lineage tracing approach. "Reporter" mice were generated whose FDCs would be stained by a blue marker if they had expressed PDGFR-β at any point in their life, even if PDGFR-β expression was suppressed at the time of analysis. Under these conditions, Krutler and Aguzzi found that FDCs express the blue marker, indicating that they stem from another cell type which had previously expressed PDGFR-β.

The final piece of evidence nailing the origin of FDCs came from a transplantation experiment. Krutler and colleagues isolated pure vascular mural cell populations from fat tissue of mice, which were then introduced into collagen sponges. The sponges were then transplanted into a special mouse strain that cannot develop FDCs. Upon induction of an inflammatory state, FDCs and lymphoid follicles were found to arise within the collagen sponges. Because the FDCs could not possibly have developed from the host animals, this experiment positively demonstrates that mural cells can give rise to FDCs.

The work that is currently being published in Cell clarifies a question that has been controversially discussed for the last 25 years. The recognition that FDCs derive from pluripotent mural cells helps understanding autoimmune and pathogen-driven chronic inflammatory conditions, the generation of FDC-derived tumors, and certain aspects of the pathogenesis of acquired immunodeficiency syndrome (AIDS) and of prion infections. Because FDCs are an important site of prion-replication outside the brain, there is reason to hope that interfering with the differentiation of vascular FDC precursors may play a positive role in preventing prion infections.


'/>"/>

Contact: Adriano Aguzzi
adriano.aguzzi@usz.ch
41-442-552-107
University of Zurich
Source:Eurekalert

Related medicine news :

1. Researchers will employ microscopic clay minerals to design more efficient and less toxic drugs
2. Tufts Medical Center researchers receive $10 million NIH grant to test blood clot prevention drug
3. Heuer M.D. Research Announces CardiaShred™ - First Medical Doctor Formulated, Heart Healthy Weight Loss, Energy and Lean Muscle Building Supplement
4. Researchers Offer Explanation for Actos Bladder Cancer Risk
5. Researchers report success in treating autism spectrum disorder
6. UCLA School of Dentistry gets $5M from NIH to train future leaders in oral health research
7. Despite hardships, black men in urban communities are resilient, MU researcher says
8. Wayne State University researcher seeks to understand link between obesity, flu severity
9. Researchers discover rare leukemia-causing protein
10. Researchers block pathway to cancer cell replication
11. Moffitt researchers find cutaneous human papillomavirus infection a risk factor for skin cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... NY (PRWEB) , ... January 20, 2017 , ... ... VW+ 001 and its sugar-free alternative VW+ 002. The drinks have been produced ... with optimal conditions to perform during your workout. , After a successful launch ...
(Date:1/20/2017)... ... January 20, 2017 , ... “I Forgive You”: a fine examination of how God ... is the creation of published author, Stephen Miller, who, for over ten long years has ... to him. Born in Trinidad and Tobago, he has been serving the Lord for over ...
(Date:1/20/2017)... ... , ... “Knowledge is God’s Lighthouse”: a moving and colorful collection of ... the creation of published author, Gene Gaapf, a retired truck driver, and a long-time ... been writing since high school and have many different titles,” Gaapf mentions about his ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... Management System: an On-demand E-learning system for Clinical and Regulatory education for ... is based on Aerolib`s successful education methodology of Disease Specific Documentation Improvement. ...
(Date:1/19/2017)... ... 19, 2017 , ... This month, the CEO and Clinical Director of Sober ... rehab center in Delray Beach, Florida has been changed from Sober Living Outpatient to ... Philip Seymour Hoffman and Chris Farley are dying from heroin overdoses, but thousands of ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... and Webcast to Follow Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... the fourth quarter of 2016 on Wednesday, February 15, 2017, after ... ... on Wednesday, February 15, 2017, during which management will discuss the ... activities. To participate in the conference call, please dial 1-888-771-4371 (domestic) ...
(Date:1/19/2017)... , Jan. 19, 2017 This report ... current and future scenario of the global market. Large ... opioid consumption. Severe chronic constipation is a major side ... traditional laxatives. Hence, novel targeted therapy has been prescribed ... sufferers, launch of targeted medicines, and growing awareness about ...
(Date:1/19/2017)... BioTherapeutics Inc. ( Stealth ), a clinical-stage biopharmaceutical company ... additions to its senior leadership team: W. Douglas ... Daniel Geffken as interim Chief Financial Officer. In ... has been promoted to Chief Clinical Development Officer. ... Daniel to our management team, as both will be ...
Breaking Medicine Technology: